References

Heartburn and Acid Reflux Cure Program

Alternative Cure for Acid Reflux

Get Instant Access

Anonymous Risk assessment for senna during pregnancy. Pharmacology 1992; 44(Suppi 1): 20-22.

Alstead EM, Nelson PC Inflammatory bowel disease in pregnancy. Gut 2003; 52: 159-61.

Bailey B. Addis A, Lee A et at. Cisapride use during human pregnancy: a prospective, controlled multicenter study. Dig Dis Sei 1997: 42; 1848-52.

Batocchi AP, Majollni L, Evoli A et al. Course and treatment of myasthenia gravis during pregnancy. Neurology 1999; 52: 447-52.

Bellemin B, Carlicr P, Vial T et al. Misoprostol exposure during pregnancy: a French collaborative study. Presentation at the 10th Annual Conference uf the European Network of Teratology Information Services (ENTIS), Madrid. 1999.

Bonapace ES Jr. Fisher RS. Constipation and diarrhea in pregnancy. Gastroenterol Clin North Am 1998; 27: 197-211.

Bond GR, van Zee A. Overdosage of misoprostol in pregnancy. Am ] Obstet Gynecol 1994; 71: 561-2.

Broussard CN, Richter J E, Treating gastroesophageal reflux disease during pregnancy and lactation: what are the safest therapy options? Drug Saf 1998; 19: 325-37.

Cappell MS, Garcia A. Gastric and duodenal ulcers during pregnancy. Gastroenterol Clin North Am 1998; 27: 169-95.

Carmichael SL. Shaw CM. Schaffer DM el al. Dieting behaviors and risk of neural tube defects. Am | Epidemiol 2003; 158: 1127-31.

Cedergren M. Kalian B. Maternal obesity and the risk for orofacial clefts in the offspring. Cleft Palate-Craniofacial | 2005: 42: 367-71.

Cliristensen LA. Rasmussen SN. Hansen SH et al. Disposition of 5-aminosalicylic acid and N-acety!-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations. Acta Obstet Gynaecol Scand 1994; 73: 399-402.

Colombel JF. Brabant G. Gubler MC et a!. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet 1994; 344: 620-21.

Coline!] W. Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drag therapy. Drug Saf 1999; 21: 311 -23.

Correa-Villasenor A. Alverson CJ. Maternal obesity and cardiovaskular malformations. Birth Def Res A 2004; 70: 257.

De Boer NKH. van Elburg RM. Wilhelm Aj et al. 6-Thioguanine for Crohn's disease during pregnancy: thiopurine metabolite measurements in both mother and child. Scand} Gastroenterol 2005; 40; 1374-7.

Diaferia A. Nicastri PI, Tartagni N. Ursodeoxycholic acid therapy in pregnant women with cholestasis. Intl I Gynaecol Obstet 1996; 52: 133-40.

Diav-Citrin O, Park YH, Veerasuntharam G et al. T he safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998: 114: 23-8.

Diav-Citrin CO, Amon j. Shechtman S et al. The safety of proton pump inhibitors in pregnancy; a multicentre prospective controlled study. Aliment Pharmacol Thcr 200.5:21:269-75.

Domingo JL, Gomez M. Colomina MT. Risks of aluminium exposure during pregnancy. Science 2000; 1: 479-87.

Domillitz |A, Young ]CC. Boyko EJ. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am | Gastroenterol 2002; 97:641-8.

Edison Rj, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am | Med Genet A 2004; 131A: 287-98.

Edison R| (A), Muenke M. Gestational exposure to lovastatin followed by cardiac malformation misclassified as holoproscncephaly. N Engl J Med 2005; 352: 2759.

Edison RJ (B), Schnur RE. Ennis S et al. Potential teratogenicity of statin drugs : an update. Birth Def Res A 2005; 73: 298.

Einarson A, Mastroiacovo P. Amon | el al. Prospective, controlled, multicentre study of loperamide in pregnancy. Can J Gastroenterol 2000. 14: 185-7.

Einarson A, Bonari L, Sarkar M et al. Exposure to sibutramine during pregnancy: a case series. Eur | Obstet Gyn Reprod Biol 2004; 116: 112.

Fonager K. Sorensen HT. Olsen J el al. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am | Gastroenterol 1998; 93: 2426-30.

Friedman JM, Little BB. Brent RL et al. Potential human teratogenicity of frequently prescribed drugs. Obstet Gynecol 1990; 75: 594-9.

Friedman S. Regueiro MD, Pregnancy and nursing in inflammatory bowel disease. Gastroenterol Clin North Am 2002: 31: 265-73.

Garbis-Berkvens JM, Diav-Citrin O et al. Prcgnancy outcome after exposure to rani tidine and other H2-blockers. A Collaborative Study of the European Network of Teratology Information Services. Reprod Toxicol 2005; 19; 453-8.

Gatusso JM. Kamin MA. Adverse effects of drugs used in the management of constipation and diarrhoea. DrugSaf 1994; 10: 47-65.

Ghidin A, Sicherer S, Willner |. Congenital abnormalities (Vater) in baby born to mother using lovastati-n. Lancet 1992; 339: 1416-17.

Gilbert-Barness E, Barness LA. Wolff el al. Aluminum toxicity. Arch Ped Adolescent Med 1998; 152: 511-12.

Glade G. Saccar GR, Pereira GK. Cimetidine. Transient liver impairment in the newborn. Case report. Am | Dis Child 1980: 134: 87-8.

Glantz A. Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rales. Hepatology Baltimore. MD 2004; 40: 467-74.

Gordon MV. McMahon LP, Hamblin PS. Life-threatening milk-alkali syndrome resulting from antacid ingestion during pregnancy. Med | Ausl 2005; 182: 350-51.

Gregcr |L. Aluminum metabolism. Annu Rev Nutr 1993: 13: 43-63.

Hayes A, Gilbert A, Lopez, G el al. Mevacor - a new teratogen? Am J Hum Genet 1995; 57: A92.

Honein MA. Moore CA. Watkins ML. Subfertility and prepregnancy overweight/obesity: possible interaction between these risk factors in the etiology of congenital renal anomalies. Birth Def Res A 2003: 67: 572-7.

lacoby EB, Porter KB. Helicobacter pylori infection and persistent hyperemesis gravidarum. Am I Perinatal 1999: 16: 85-8.

|ones KL, Johnson KA, Dick LM et al. Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine. Teratology 2002; 65: 125-30.

Kadioglu M, Ulku C, Yaris F et al, Sibutramine use in pregnancy: report or two cases. Birth Def Res A 2004: 70: 545-6.

Källen BA. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol 1998; 105: 877-81.

Källen BA. Use of omeprazole during pregnancy - no hazard demonstrated in 955 infants exposed during pregnancy. Eur J Obstet Gynecol Reprod Biol 2001: 96: 63-8.

Katz JA, Pore G. Inflammatory bowel disease and pregnancy. Inflam Bowel Dis 2001; 7: 146-57.

Katz |A, Antoni C, Kcenan GF. et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am | Gastroenterol 2004; 99: 2385-92.

Katz PO, Castell DO. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin North Am 1998:27: 153-67.

Kobayashi T. Sugimura M. Tokunaga N et al. Anticholinergics induce eclamptic seizures. Semin T'hromb Hemost 2002; 28: 511 -14.

Kondrackiene J. Beuers U. Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005: 129: 894-901.

Kornfeld I), Cnattingius S, Kkbom A. Pregnancy outcomes in women with inflammatory bowel disease - a population-based cohort study. Am J Obstet Gynecol 1997; 177: 942-6.

Lalkin A. Loebstein R. Addis A et al. The safety of omeprazole during pregnancy: a multicentcr prospective controlled study. Am J Obstet Gynecol 1998; 179(3 Pt 1): 727-30.

Landon MB. Soloway RD, Freedman l.| et al. Primary sclerosing cholangitis and pregnancy. Obstel Gynecol 1987: 69: 457.

Larraz J, Marin N, Pineiro L et al. Lack of relationship between infection by Helicobacter pylori and vomiting that usually occurs during pregnancy, although possible relationship with severe forms of emesis. Rev Esp Enferm Dig 2002; 94: 417-22.

Levi S, Liberman M, Levi A| et al. Reversible congenital neutropenia associated with maternal sulphasalizine therapy {Letter}. Euro | Pediatr 1988: 48: 174-5.

Magee LA. Inocencion C, Kamboj L et al. Safety of first trimester exposure to histamine I l2-blockers. Dig Dis Sei 1996: 41: 1145-9.

Manson JM. Freyssinges C, Ducrocq MB ct al. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol 1996; 10: 439-46.

Marteau P, Tennenbaum R. Elefant F. et al. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther 1998; 12: 1101-18.

McDonald jA. Cholestasis of pregnancy. J Gastroenterol Hepatol 1999: 14: 515-18.

McKenna D, Watson P. Dornan J. Helicobacter pylori infection and dyspepsia in pregnancy. Obstet Gynecol 2005: 102: S45-9.

Nikfar S. Abdollahi M, Moretti MF, et al. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sei 2002: 47: 1526-9.

Norgärd B. Fonager K. Sorensen HT el al. Birth outcomes of women with ulcerative coli lis: a nationwide Danish cohort study. Am ( Gastroenterol 2000; 95: 3165-70.

Norgird B. Erzsebel P. Pedersen L et al. Risk of congenital abnormalities in children born to women with ulcerative colitis: a population-based, case-control study. Am I Gastroenterol 2003: 98: 2006 10,

Palma J, Reyes H, Hibalta | et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy. A randomised double blind sludy controlled with placebo. I Hepatol 1997; 27: 1022-8.

Polizzi A, Huson SM. Vincent A. Teratogen update: maternal myasthenia gravis as a cause of congenital arthrogryposis. Teratology 2000; 62: 332-41.

Pollack PS, Shields KE. Burnett DM et al. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Def Res A 2005; 73: 888-96.

Prajapati DN, Newcomer |R, Emmons | et al. Successful treatment of an acutc flare of steroid-resistant Crohn's colitis during pregnancy with unfractionated heparin. Inflam Bowel Dis 2002; 8: 192-5.

Priest ND. The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing 2f>Al as a tracer: review and study update. J Environ Monit 2004; 6: 375-403.

Reyes H. Sjovall [. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann Med 2000; 32: 94-106.

Richter JE. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin North Am 2003; 32:235-61.

Robert E, Francannet CH, Shaw G Neural tube defects and maternal weight reduction in early pregnancy. Reprod Toxicol 1994; 8: 448.

Robert E, Francannet CH, Shaw G el al Neural tube defects and maternal weight reduction in early pregnancy. Reprod Toxicol 1995; 9: 57-9.

Robertson WC Jr. Calcium carbonate consumption during pregnancy: an unusual cause of neonatal hypocalcemia. [ Child Neurol 2002; 17: 853-5.

Roncaglia N. Locatelli A, Arreghini et at. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-1-methionine in the treatment of gestational cholesla sis. Br! Obstet Gynecol 2004; 111: 17-21.

Rost van Tanningen MM. Schaefer C. Elefant E el al. Pregnancy outcome after expo sure to mesalazine. A Collaborative Study of the European Network of Teratology Information Services (ongoing).

Roux C, Wolf C, Mulliez N el al. Role of cholesterol in embryonic development. Am I Clin Nutr 2000: 71(5 Suppi): S1270-79.

Ruigomez A, Gargia-Rodrigucz LA. Cattaruzzi C el al. Use of Cimetidine, omeprazole, and ranitidine iti pregnant women and pregnancy outcomes. Am J Epidemiol 1999; 150: 476-81.

Sadler LC. Lane M, North R. Severe fetal haemorrhage during treatment with cholestyramine for intrahepatic cholestasis of pregnancy. Br J Obstet Gynaecol 1995; 102: 169-70.

Scialli AR. Teratology Public Affairs Committee Position Paper: Maternal obesity and pregnancy. Birth Dei Res A 2006; 76: 73-7.

Schindler AM Isolated neonatal [Hypomagnesemia associated with maternal overuse of stool softener. Lancet 1984; 2: 822.

Shaw GM (A), Todoroff K, Finnell RH et al. Spina bifida phenotypes in infants or fetuses of obese mothers. Teratology 2000: 61: 376-81.

Shaw GM (B). Todoroff K, Carmichael SL ct al. Lowered weight gain during pregnancy and risk of neural lube defects among offspring {Abstract). Teratology 2000: 61:451.

Steingrub JS, Lopez T. Teres D el al. Amniotic fluid embolism associated with castor oil ingestion. Crit Care Med 1988; 16: 642-3.

Tellez-Zenteno JF. Hernández-Ronquillo L. Salinas V et al. Myasthenia gravis and pregnancy: clinical implications and neonatal outcome. HMC Musculoskcl Dis 2004: 5: 42.

Vial T, Roberl E, Carlier P et al. First-trimester in utero exposure to anorectics: a French collaborative study with special reference to dexfenfluramine. Intern ) Risk Sai Med 1992; 3: 207-14.

Weyermann M, Brenner H. Adler G et al. Helicobacter pylori infection and the occurrence and severity of gastrointestinal symptoms during pregnancy. Am | Obstet Gynecol 2003: 189: 526-31.

Wiesel A, Stolz G, Schlaefer K et al. Does maternal obesity increase the risk of congenital anomalies? Reprod Toxicol 2001: 15: 561-85.

Zapata R, Sandoval L, Palma | et al. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience. Liver Intl 2005; 25: 548-54.

Was this article helpful?

0 0
Natural Weight Loss

Natural Weight Loss

I already know two things about you. You are an intelligent person who has a weighty problem. I know that you are intelligent because you are seeking help to solve your problem and that is always the second step to solving a problem. The first one is acknowledging that there is, in fact, a problem that needs to be solved.

Get My Free Ebook


Post a comment